ADAURA
2020
Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC
In 682 patients with completely resected stage IB–IIIA EGFR-mutated NSCLC, three years of adjuvant osimertinib improved disease-free and overall survival compared with placebo.
Result
Efficacy: DFS in stage II–IIIAHR 0.17
Below 1 favours three years of adjuvant osimertinib, above 1 favours placebo.
Also reported: Final OS HR 0.49 (5-yr OS 85% vs 73% in II–IIIA).
- Subtopic
- EGFR adjuvant
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Wu YL, et al. N Engl J Med. 2020;383(18):1711-1723; Tsuboi M, et al. N Engl J Med. 2023;389(2):137-147.doi 10.1056/NEJMoa2027071
Discussion & critique
Established adjuvant osimertinib after resection in EGFR-mutated NSCLC. Optimal duration and stage IB subgroup remain debated.